Table 1. Baseline demographics and characteristics.
| Empagliflozin | Placebo (n = 21) | Total (n = 100) | ||||
|---|---|---|---|---|---|---|
| 1 mg (n = 19) | 5 mg (n = 21) | 10 mg (n = 20) | 25 mg (n = 19) | |||
| Men, n (%) | 16 (84.2) | 20 (95.2) | 17 (85.0) | 15 (78.9) | 16 (76.2) | 84 (84.0) |
| Median (range) age (years) | 58.0 (43–70) | 54.0 (34–67) | 57.5 (42–70) | 61.0 (42–70) | 59.0 (38–70) | 59.5 (34–70) |
| Median (range) bodyweight (kg) | 63.1 (45.0–93.4) | 74.8 (51.7–90.7) | 68.7 (43.4–98.0) | 62.5 (48.0–89.3) | 71.9 (47.6–98.3) | 68.0 (43.4–98.3) |
| Median (range) waist circumference (cm) | 84.8 (69.0–104.5) | 89.2 (77.8–102.2) | 87.0† (73.7–115.0) | 87.0 (75.5–100.3) | 91.0 (75.0–112.8) | 87.5 (69.0–115.0) |
| Median (range) BMI (kg/m2) | 22.4 (19.1–32.6) | 25.1 (21.2–39.1) | 24.0 (19.2–31.5) | 24.7 (18.0–30.0) | 26.4 (20.1–34.6) | 24.3 (18.0–39.1) |
| Mean (SD) UGE (g) | ||||||
| Day −1 | 12.6 (12.0) | 7.6 (11.6) | 10.5 (12.4) | 9.2 (14.6) | 5.8 (8.7) | 9.1 (11.9) |
| Day −2‡ | 17.9 (15.4) | 8.4 (8.0) | 15.6 (12.6) | 7.6 (8.6) | 9.1 (13.5) | 11.6 (12.4) |
| Mean (SD) eight‐point glucose, mmol/L (Day −2) | 11.9 (2.0) | 10.2 (1.7) | 11.2 (1.7) | 10.6 (1.6) | 10.3 (1.5) | 10.8 (1.8) |
| Mean (SD) FPG, mmol/L (Day −1) | 9.5 (1.8) | 8.6 (1.4) | 8.9 (1.7) | 8.9 (1.3) | 8.8 (1.3) | 8.9 (1.5) |
| Mean (SD) HbA1c, % (Day −1) | 8.5 (0.9) | 7.8 (0.7) | 8.2 (0.7) | 8.0 (0.8) | 8.0 (0.7) | 8.0 (0.8) |
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; SD, standard deviation; UGE, urinary glucose excretion. †n = 19. ‡n = 18, 19 and 18 for empagliflozin 1, 10 and 25 mg, respectively.